The surgical risk of transplanted patients is high, and the modified gastrointestinal anatomy after bariatric surgery (BS) may lead to pharmacokinetic alterations in the absorption of immunosuppressive drugs. Data on outcomes of BS and the safety and feasibility of maintaining immunosuppression and graft safety among solid organ transplanted patients are scarce. In the current study, weight loss, improvement in comorbidities, and changes in dosage and trough levels of immunosuppression drugs before and after BS were analyzed for all transplanted patients who underwent laparoscopic sleeve gastrectomy (LSG) or laparoscopic Roux-en-Y gastric bypass (LRYGB) in our institution between November 2011 and January 2017. Thirty-four patients (13 females, 21 males, average age 53 years) were included in the study. A successful weight loss (>50% excess weight loss in 28 of them [82%]) was recorded at the last follow-up. Comorbidities improved significantly. Immunosuppressive stability increased from 39% to 47% among all patients. The tacrolimus blood trough levels declined slightly, but remained within therapeutic range. These data suggest that LSG and LRYGB ensure good immunosuppressive maintenance together with significant weight loss and improvement in comorbidities without serious graft rejection or dysfunction. The surgical risk is higher than in the regular BS population.
| INTRODUC TI ON
Obesity has become a global pandemic, with more than one third of the population meeting the criteria for obesity. 1 It is commonly associated with comorbidities, such as heart and renal disease and nonalcoholic steatohepatitis which, in turn, can lead to an end-stage organ failure. 2 Bariatric surgery (BS) is the most effective solution for morbid obesity (MO), and the number of patients undergoing it is rapidly and constantly growing. 3, 4 Patients with end-stage organ failure comprise a subgroup of obese individuals.
They may undergo organ transplantations, and additional weight gain following the procedure occurs in the majority of kidney and liver transplant (LT) recipients, 5, 6 with the major cause of mortality being associated with cardiovascular sequelae related to obesity. The only successful remedy for these patients in the long run is a BS, with the inevitable changes in the gastrointestinal anatomy. This modified anatomy of the patient may lead to significant pharmacokinetic (PK) postoperative alterations in the oral absorption of drugs, and yet there are very few publications on the effects of the surgery on drug absorption. [7] [8] [9] BS is thought to change several critical steps in drug absorption, including disintegration, dissolution, bypass of the absorption site (such as in bypass surgeries), and bypass of metabolism sites in the intestine by enzymes and efflux pumps. 7 The effect of BS on PK changes of calcineurin inhibitors was reported in a small study of 6 patients with dissimilar postsurgery time intervals. 10 The aim of the present study was to retrospectively investigate the PK changes in medication, graft survival, weight loss, and improvement in comorbidities of patients undergoing BS following kidney, liver, or heart transplantation.
| ME THODS

| Patient selection
The prospective data collection was approved by the Institutional 
| Operative management
The surgical techniques of LSG and LRYGB were the same as those widely described and discussed in the literature.
| Postoperative management
The patient was started on clear liquids on postoperative day 1.
The patients were followed routinely at the BS Clinic at 2 weeks, and 3, 6, and 12 months, and annually thereafter. They continued a separate follow-up at the designated transplant clinic with appropriate graft function tests, and dosage and plasma levels of immunosuppressive drugs.
| Statistical analysis
Descriptive and comparative statistics were performed using SAS version 9 (SAS Institute Inc., NC). Pre-and postsurgery immunosuppressive drug doses and levels were used to present individual patient data, and 95% confidence intervals for mean differences in drug levels and dosage in the 2 surgical groups were calculated by analysis of variance and paired t tests. Continuous variables were reported as mean and range unless otherwise specified, and they were compared using the unpaired t test (Student t test). P ≤ .05 were considered to indicate statistical significance. The subgroups were too small to get any statistically significant results, so the results are presented only as descriptive.
| RE SULTS
Thirty-eight transplanted patients underwent BS in our institute Patients whose preoperative trough levels were within the normal range tended to stay balanced after surgery, while abnormal preoperative values also persisted following surgery. The small number of subjects precluded the establishment of significance in most of the analyses. It could, however, be observed that the blood trough levels of tacrolimus slightly declined, but remained within the therapeutic range ( Figure 3) .
None of the patients required any significant tacrolimus dosage adjustment ( Figure 3 ). There was also no change in the mycophenolic acid or prednisone dosages for all the subjects listed.
The bariatric procedure results at the 1-year (n = 34) and 3-year (n = 19) follow-up are presented in Table 1 Thirty eight transplanted patients underwent BS in our institute. Three of them underwent simultaneous liver transplantation and SG.
EXCLUDED -1 patient received Cyclosporine.
Statistical analysis data was derived from the 33 patients treated with Tacrolimus at least 1 year previous to BS and during all the follow-up period.
Immunosuppression drugs analysis Weight loss analysis
Statistical analysis data was derived from the whole study group of 34 patients who had at least 1 year follow-up after BS. Thirty four patients included in the study (follow-up time of 1 to 5 years) 34 -after renal (n=29), liver (n=4) and heart (n=1) transplantation underwent BS for MO One patient with an initial BMI of 70 who previously underwent gastric banding had no weight loss with LSG and he underwent a second-stage biliopancreatic diversion and duodenal switch 11 14 months later. His data were excluded from the study from then on. Another patient had 2 perioperative complications.
Obesity-related diseases analysis
The minor complication was acute renal failure with an elevation of serum creatinine level to 2.4 mg/dL due to recurrent vomiting secondary to a sleeve stricture, which was successfully treated with hydration. The sleeve stricture, which was initially treated unsuccessfully by pneumatic dilatation, finally required conversion to a LRYGB 6 weeks after the primary operation. That patient's data are included in the LRYGB study group. One of the 4 livertransplanted patients had undergone LRYGB with an early com- was referred to the BS clinic 6 months after the transplantation due to the rapid development of a huge incisional hernia that was not amenable to repair without a preceding significant weight loss.
The cause of mortality was an anastomotic leak from a gastrojejunal anastomosis on day 9 after LRYGB and ensuing sepsis.
| D ISCUSS I ON
With the considerable expansion of experience in BS, patients who had previously been considered inoperable can now undergo surgery with reasonable safety. Examples of these individuals include septuagenarians, adolescents, and patients with inflammatory bowel disease, all of which had been formerly considered contraindications for such surgery. Also included among them were transplanted patients. BS has been uncommon among transplant candidates and recipients, despite their having otherwise been qualified to undergo it. Its use has been impeded by the high surgical risk, the technical complexity, and the presumed altered immunosuppression absorption, with the subsequent allograft rejection as a theoretical concern among transplant recipients. With the advancement in transplant medicine, however, 5-and 10-year graft survivals are no longer an issue, and patients whose lives were prolonged after organ replacement are dying of obesity-related comorbidities. 12 These patients pose a multidisciplinary challenge due to multiple comorbidities, use of immunosuppressive agents, risk of graft dysfunction or rejection, and history or current status as patients with insufficiency of 1 or more systems. Due to these limitations, such patients had been considered inoperable, but they are now beginning to enjoy the benefits of BS. F I G U R E 2 Tacrolimus blood trough levels before and after LRYGB and LSG. Percentages of tacrolimus blood trough levels (>1 year of transplantation) falling within the therapeutic range (kidney, liver, and heart transplant = 5-7 ng/mL, 4-6 ng/mL, and 5-15 ng/mL, respectively) increased from 29 F I G U R E 3 Tacrolimus blood trough levels and drug dose (mg/day) before and after LRYGB and LSG. LSG, laparoscopic sleeve gastrectomy; LRYGB, laparoscopic Roux-en-Y gastric bypass. Tacrolimus blood trough levels therapeutic range for kidney, liver, and heart transplant were 5-7 ng/mL, 4-6 ng/mL. and 5-15 ng/mL, respectively [Color figure can be viewed at wileyonlinelibrary.com] 
roids. Weight gain following transplantation is very common, and
it occurs in the majority of kidney and LT recipients. 5 Hoogeveen et al found that the prevalence of obesity increased from 5.6% before the transplantation to 11.5% 1 year after it, and that obesity at 1 year posttransplantation increased the risk of mortality and graft failure approximately 40% compared with normal weight.
6
Morbidly obese patients with end-stage organ failure undergo more frustration and stress than nonobese patients before transplantation, which may be delayed while waiting for a suitable organ. 14 In addition, they face a higher risk of surgical complications during transplantation, and have higher rates of death and graft failure in the long term. 
| BS and transplantation
Although there is limited experience worldwide in treating post- from the weight loss and consequent metabolic improvement should be balanced against an increased surgical risk. The 2.6% mortality in our study is a much higher figure than the average 0.1%-0.31% in a general bariatric series, 20 but is similar to other series of transplanted patients. 21 In general, the sample sizes of the published series are too small to arrive at any firm conclusions regarding the risk/ benefit ratio.
It should be noted that in the first several years, we chose LSG as the procedure of choice for transplanted patients due to its relatively shorter operative time, technical simplicity, lower overall morbidity, and the fact that it is a purely restrictive and nonmalabsorptive procedure. We thought that these would pose critical advantages in patients at high risk for complications that are also dependent on immunosuppressive medications. This was when our first report was published. 22 With time and experience, we realized that LSG is less effective in the long term than previously thought and is also problematic since leaks after LSG tend to have a chronic course as opposed to leaks after RYGB that generally heal better.
In addition, other centers did not report a change in immunosuppressive drug dosage post RYGB, and since patients are under such rigorous follow-up of blood levels of immunosuppressive drugs, the benefit of LSG as a nonmalabsorptive surgery becomes quite redundant. Consequently, we started performing both LSG and LRYGB, with basically the identical considerations to the nontransplant population:
1. Gastroesophageal reflux and hiatal hernia are relative contraindications to the LSG.
2.
Chronic ulcer disease (peptic or erosive) is a contraindication to LRYGB (it is an ulcerogenic operation).
3.
Technical: multiple previous abdominal surgeries are relative contraindications to LRYGB (to avoid additional risk related to adhesions).
4.
Type of transplanted organ: in our experience all LT patients have had a choledocho-choledochal anastomosis, but presumed choledocho-jejunal anastomosis would preclude LRYGB.
5.
In 2 patients with previous peritoneal dialysis, severe adhesions were encountered; therefore, intraoperatively the planned LRYGB was changed to LSG.
The type of organ transplant did not play any role in the decision.
We recommended that the bariatric operation be done at least 1 year after the transplantation and previous surgical experience, mainly with the intention of achieving desirable abdominal conditions.
| BS and antirejection medications
PK changes of medications have been exhibited in drugs, such as warfarin, where lower doses were required for the first 6 months postsurgery, 23 and sertraline, which showed a significant decrease in area under the curve (AUC) and maximum serum concentration (Cmax) when compared between LRYGB patients and controls.
Several studies have shown that this effect might be transient for some medications, such as duloxetine, midazolam, and more.
24
There are several studies supporting the safety and efficacy of BS. 22 In the transplant population, however, data are lacking on how BS may alter the PK of modern immunosuppression, such as calcineurin inhibitors, particularly tacrolimus. Tacrolimus is a medication that has a narrow therapeutic index with a large intra-and interindividual variability in its PK. It is affected by drug interactions, liver function, and type of transplanted organ, and thus requires monitoring of blood concentrations and an individualized dosage regimen design. 25 The oral formulation is known to be absorbed mainly in the proximal duodenum; however, it was shown in a model of short-bowel piglets that the drug can be absorbed from the colon as well. 8, 26 Our results support the feasibility and relative safety of BS among transplanted patients. The %EWL reported in LSG and LRYGB ranges widely, from 33% to 90% and from 49% to 62%, 27 respectively. At 3 years of follow-up, the mean %EWLs of LSG and of LRYGB transplanted patients were 84% and 83%, respectively, and the total mean %WL of 32% was higher than that produced by the general bariatric patient population (%WL of 31% for LRYGB and 20% for LSG). This finding is highly relevant in this group. 14, 28, 29 In some studies the obesity does not predict worse outcomes in kidney-and liver-transplanted patients, although most of the evidence shows obesity and obesity-related comorbidities to be a risk factor for graft loss and patient death. 15, 16, 28 A recent PK study by Rogers et al 10 This study has several limitations. It lacks a control group, and comparison of the patients to a MO group without a bariatric intervention would further clarify whether there is a measurable benefit.
Second, an additional PK investigation is needed in order to determine whether different bariatric surgeries have distinct implications on renal-, liver-and heart-transplanted patients. Third, a larger series with a longer follow-up (5-10 years) could provide solid evidence of the positive effect of BS on graft survival.
| CON CLUS IONS
When considering BS in posttransplant patients, it is of equal importance to achieve both weight loss and improvement in comorbidities concomitantly with immunosuppressive stability. Our results suggest that SG and LRYGB ensure significant weight loss and improvement of associated diseases, together with good immunosuppressive maintenance, along with the absence of serious graft rejection or dysfunction and with an acceptable mortality of 2.6% in this high surgical risk population.
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